Longevity-Focused Peptides: Class Overview

“Longevity peptides” is a topic grouping, not a coherent drug class and not evidence that any member extends human life. Epitalon, MOTS-c, and SS-31 differ in sequence, origin, target hypothesis, and evidence stage. NAD+ is not a peptide at all; it is included because NAD+ precursor studies are commonly discussed alongside mitochondrial and aging-focused peptide research.

The organizing framework comes from the hallmarks-of-aging literature. The 2013 paper proposed nine hallmarks (PMID 23746838); the 2023 update expanded the framework to twelve, adding disabled macroautophagy, chronic inflammation, and dysbiosis (PMID 36599349). A hallmark is a research framework, not a validated surrogate for longer life in humans.

Research context: This page is for scientific education. It does not provide medical advice, dosing, sourcing, or a recommendation to use an investigational compound.

What Belongs in This Overview

Entry	Molecular category	Main research anchor	Evidence boundary
Epitalon	Synthetic tetrapeptide, Ala-Glu-Asp-Gly	Telomere and gene-regulation experiments	Cell studies do not establish human lifespan or clinical benefit
MOTS-c	16-amino-acid mitochondrial-derived peptide	Metabolic stress signaling and AMPK-related preclinical work	The discovery paper is primarily cell and mouse evidence
NAD+	Dinucleotide cofactor, not a peptide	NAD+ metabolism and precursor trials	Raising blood NAD+ is not the same as improving clinical outcomes
SS-31 Dose-Response	Mitochondria-targeted tetrapeptide; elamipretide	Inner-mitochondrial-membrane and cardiolipin-related research	FDA accelerated approval is limited to eligible patients with Barth syndrome; other uses remain investigational

Grouping these entries together is useful only if the distinctions remain visible. Evidence cannot be transferred from one to another.

Hallmarks of Aging: A Map, Not an Outcome

A mechanistic study can show that a compound changes a telomere measurement, metabolite, mitochondrial readout, or transcriptional profile. It does not follow that the compound slows organismal aging, extends lifespan, or improves how a person feels or functions.

A strong translation chain requires separate evidence at each step:

flowchart TD
    ID["Confirmed molecular identity"] --> EXP["Measured exposure"]
    EXP --> TARGET["Target engagement"]
    TARGET --> CELL["Cellular or molecular change"]
    CELL --> ORGAN["Organ-level function"]
    ORGAN --> CLIN["Prespecified clinical outcome"]
    CLIN --> DUR["Durability and safety"]

    EPI["Epitalon"] -. "telomere / transcription hypotheses" .-> TARGET
    MOTS["MOTS-c"] -. "metabolic stress signaling" .-> TARGET
    NAD["NAD+ precursors"] -. "NAD+ metabolome" .-> TARGET
    SS31["SS-31 / elamipretide"] -. "mitochondrial membrane" .-> TARGET

Most claims in this field stop before the clinical-outcome and durability steps.

Epitalon: Telomere Findings Need a Translation Boundary

Epitalon—also spelled Epithalon in older publications—is the tetrapeptide Ala-Glu-Asp-Gly. A 2003 study reported telomerase activity and telomere elongation in human somatic-cell cultures (PMID 12937682). A 2025 cell-line study also reported increased telomere length while finding evidence consistent with either telomerase upregulation or alternative lengthening of telomeres, depending on the cell system (PMID 40908429); the journal later published a correction to that article (PMID 41240216).

These are in-vitro findings. They do not establish that administering Epitalon lengthens telomeres in people, improves healthspan, prevents disease, or extends human life. Telomere length is also not a stand-alone clinical endpoint: assay method, cell type, baseline length, cell turnover, and cancer biology all affect interpretation.

Older Epitalon and epithalamin literature includes animal and small human reports, often from a limited set of research groups. This page does not convert those reports into a lifespan claim because independent, preregistered human trials with clinically meaningful endpoints are not established by the cited sources.

MOTS-c: Strong Discovery Biology, Early Human Translation

MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA region. The 2015 discovery paper reported metabolic effects in cell and mouse models, including AMPK-related signaling and improved metabolic homeostasis in mice (PMID 25738459). That paper supports the identity and preclinical mechanism; it does not establish efficacy or safety of exogenous MOTS-c in humans.

Circulating associations are not equivalent to intervention effects. A lower measured MOTS-c concentration in an older or metabolically impaired group cannot show that replacement reverses the condition. Assay validation, tissue source, sex, exercise state, kidney function, and sampling conditions can all affect a biomarker result.

As of the access date, ClinicalTrials.gov lists a phase 2a placebo-controlled study of MOTS-c in adults with prediabetes and overweight or obesity, with completion expected after 2026 (NCT07505745, accessed September 4, 2026). Registration describes a planned experiment; it is not a result.

NAD+ and Precursors: Separate Biochemistry from Outcomes

NAD+ participates in redox reactions and serves as a substrate for enzymes including sirtuins and PARPs. The 2004 NR-pathway paper identified nicotinamide riboside as an NAD+ precursor and characterized conserved NR kinase pathways in fungi and humans (PMID 15137942).

Age-related NAD+ biology is not uniform across every tissue or species. A 2013 mouse study linked declining NAD+ to altered nuclear–mitochondrial communication and reported effects of restoring NAD+ in that model (PMID 24360282). Another mouse study identified age-associated increases in CD38 activity and linked them to NAD+ decline and mitochondrial dysfunction (PMID 27304511). Those studies do not by themselves establish the same causal magnitude in humans.

Human precursor studies answer narrower questions. A 2016 pharmacokinetic study showed dose-dependent changes in the blood NAD+ metabolome after oral nicotinamide riboside (PMID 27721479). A 2018 randomized crossover trial in healthy middle-aged and older adults found that chronic NR supplementation was well tolerated in that study and increased NAD+-related measures (PMID 29599478). Neither result establishes longer life, broad disease prevention, or class-wide functional benefit.

Direct NAD+, NR, and NMN are different interventions. Their absorption, metabolism, exposure markers, and clinical evidence should not be merged under the statement that they all “restore NAD+.”

SS-31 / Elamipretide: Mechanism Does Not Guarantee Trial Success

SS-31, also called elamipretide in clinical development, is an aromatic-cationic tetrapeptide studied at the inner mitochondrial membrane. Mechanistic literature describes interaction with cardiolipin-rich membranes and effects on cytochrome-c/cardiolipin behavior, electron transport, and membrane electrostatics (PMID 24134698; PMID 32273339). These sources support a membrane-centered mechanism; they do not support a universal claim that SS-31 repairs mitochondria in every disease.

Clinical outcomes have depended on indication and trial. In the phase III MMPOWER-3 trial in genetically confirmed primary mitochondrial myopathy, subcutaneous elamipretide did not improve either primary endpoint—the six-minute walk test or the study’s fatigue score—at 24 weeks versus placebo (PMID 37268435; NCT03323749). Calling SS-31 “phase III” without reporting that result would materially mislead readers.

In September 2025, FDA granted accelerated approval to elamipretide (Forzinity) to improve muscle strength in adults and children with Barth syndrome who weigh at least 30 kg. Continued approval may depend on verification of benefit; the decision does not establish efficacy in aging or other mitochondrial conditions (FDA Drug Trials Snapshot).

Earlier heart-failure studies were smaller and addressed different questions. A randomized phase II HFrEF trial evaluated 28 days of treatment and did not establish a general anti-aging indication (PMID 32068002). Clinical development status should therefore be stated by trial, population, endpoint, and date—not as proof that the mechanism works clinically.

Comparison by Evidence Layer

Evidence layer	Epitalon	MOTS-c	NAD+ precursors	SS-31 / elamipretide
Molecular identity	Defined tetrapeptide	Endogenous mitochondrial-derived peptide	Multiple distinct nonpeptide precursors and NAD+ itself	Defined tetrapeptide
Primary mechanistic evidence	Telomere and transcription experiments	Metabolic-stress signaling in cells and mice	NAD+ biosynthesis and metabolism	Cardiolipin-rich membrane interaction
Human exposure evidence	Limited in the cited modern sources	Registered study; results not yet established	Multiple human NR/NMN studies, intervention-specific	Multiple indication-specific trials
Clinical efficacy	No human longevity conclusion from cited cell work	Not established by the discovery paper or pending registry	Biomarker increases do not establish broad functional benefit	FDA accelerated approval for eligible Barth syndrome patients; phase III PMM primary endpoints were not met
Main overstatement risk	“Activates telomerase” becomes “extends human life”	Endogenous association becomes replacement efficacy	Higher blood NAD+ becomes anti-aging benefit	Mechanistic and trial-phase language hides negative endpoints

Safety and Regulatory Boundaries

Mechanism does not establish safety. Telomere manipulation, metabolic signaling, NAD+-consuming pathways, and mitochondrial membrane effects each have context-dependent consequences. Safety must be evaluated for the exact molecule, formulation, route, population, duration, and co-interventions.

FDA’s July 2026 Pharmacy Compounding Advisory Committee materials separately evaluated Epitalon- and MOTS-c-related bulk drug substances and stated that the reviewed substances were not components of FDA-approved drugs (FDA PCAC briefing materials, accessed September 4, 2026). An ingredient listing, research paper, clinical-trial registration, or use outside the United States is not FDA approval.

Published short-term tolerability in one trial does not exclude uncommon, delayed, or off-target effects. Likewise, a negative efficacy trial does not by itself prove toxicity; efficacy and safety are separate questions.

Research Outlook and Open Questions

Epitalon: Can independent laboratories reproduce target engagement, and do any effects translate from cultured cells to prespecified human outcomes?
MOTS-c: What are the pharmacokinetics, tissue exposure, immunogenicity, and clinical effects of the exact exogenous peptide in humans?
NAD+ precursors: Which tissue measurements change, and do those changes improve validated function rather than only blood metabolites?
SS-31: Which mechanistically defined populations, if any, show clinically meaningful benefit despite negative primary outcomes in PMM?
All entries: Are findings durable, replicated, and measured against appropriate controls with complete adverse-event reporting?

No cited evidence establishes that combining these compounds extends life or produces additive benefit. Distinct mechanisms are a rationale for an experiment, not evidence of synergy.

Compound Hubs

This page is for research and educational purposes. It does not constitute medical advice, dosing guidance, or a recommendation to use any compound.

References

López-Otín C, et al. The hallmarks of aging. Cell. 2013. PMID 23746838.
López-Otín C, et al. Hallmarks of aging: An expanding universe. Cell. 2023. PMID 36599349.
Khavinson VKh, et al. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine. 2003. PMID 12937682.
Khavinson V, et al. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biochemistry and Biophysics Reports. 2025. PMID 40908429.
Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015. PMID 25738459.
Bieganowski P, Brenner C. Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans. Cell. 2004. PMID 15137942.
Gomes AP, et al. Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell. 2013. PMID 24360282.
Camacho-Pereira J, et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metabolism. 2016. PMID 27304511.
Trammell SAJ, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nature Communications. 2016. PMID 27721479.
Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications. 2018. PMID 29599478.
Szeto HH. Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis. British Journal of Pharmacology. 2014. PMID 24134698.
Mitchell W, et al. The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action. Journal of Biological Chemistry. 2020. PMID 32273339.
Karaa A, et al. Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial. Neurology. 2023. PMID 37268435.
Butler J, et al. Effects of elamipretide on left ventricular function in patients with heart failure with reduced ejection fraction: the PROGRESS-HF phase 2 trial. Journal of Cardiac Failure. 2020. PMID 32068002.
ClinicalTrials.gov. MOTS-c for improving insulin sensitivity in adults with prediabetes and overweight/obesity. NCT07505745.
U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee briefing materials. July 23–24, 2026. Official FDA document.
Correction: Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biochemistry and Biophysics Reports. 2025. PMID 41240216.